Obseva SA (OBSV) Receives $20.33 Consensus PT from Analysts
Shares of Obseva SA (NASDAQ:OBSV) have earned an average rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.33.
Several brokerages have weighed in on OBSV. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Obseva in a report on Monday, February 5th. Royal Bank of Canada restated a “buy” rating and set a $22.00 price target on shares of Obseva in a report on Thursday, November 2nd. BMO Capital Markets began coverage on Obseva in a report on Monday, December 4th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Zacks Investment Research upgraded Obseva from a “sell” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Wednesday, October 18th.
A number of hedge funds and other institutional investors have recently modified their holdings of OBSV. Sphera Funds Management LTD. increased its holdings in Obseva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after purchasing an additional 28,700 shares during the period. VHCP Management II LLC increased its holdings in shares of Obseva by 834.2% in the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock valued at $11,407,000 after acquiring an additional 1,251,343 shares during the last quarter. Abingworth LLP purchased a new position in shares of Obseva in the 3rd quarter valued at about $3,480,000. Iguana Healthcare Management LLC increased its holdings in shares of Obseva by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after acquiring an additional 20,000 shares during the last quarter. Finally, First Manhattan Co. purchased a new position in shares of Obseva in the 4th quarter valued at about $9,760,000. Institutional investors own 41.30% of the company’s stock.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01). Obseva’s quarterly revenue was up NaN% on a year-over-year basis. analysts forecast that Obseva will post -2.31 earnings per share for the current year.
WARNING: “Obseva SA (OBSV) Receives $20.33 Consensus PT from Analysts” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/14/obseva-sa-obsv-receives-20-33-consensus-pt-from-analysts.html.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.